Adalimumab: In non-radiographic axial spondyloarthritis

Drugs

Volumn 72, Issue 18, 2012, Pages 2385-2395

  Burness, Celeste B ^a   Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adalimumab; Adis Drug Profiles; Spondylarthritis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA B27 ANTIGEN; HYDROXYCHLOROQUINE; ISONIAZID; LYMPHOTOXIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROTEIN P55; PROTEIN P75; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL PAIN; ACUTE HEPATITIS; AGRANULOCYTOSIS; ANEMIA; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; AXIAL SPONDYLOARTHRITIS; BACKACHE; BIBLIOGRAPHIC DATABASE; BREAST DYSPLASIA; CHILL; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; ENTEROPATHIC ARTHRITIS; EXFOLIATIVE RASH; FEVER; HEMATOLOGIC DISEASE; HEPATITIS B; HERPES VIRAL PNEUMONIA; HUMAN; IMMUNOGENICITY; INDUCED ABORTION; INFECTION; INFLAMMATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEUKOPENIA; LIPID BLOOD LEVEL; LIVER ENZYME BLOOD LEVEL; LOWER RESPIRATORY TRACT INFECTION; LUPUS LIKE SYNDROME; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN PROTEIN INTERACTION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REACTIVE ARTHRITIS; RELAPSE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SACROILIAC JOINT; SACROILIITIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SPINE; SPINE RADIOGRAPHY; SPONDYLARTHRITIS; SYMPTOM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TREATMENT OUTCOME;

EID: 84871185815     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11470250-000000000-00000     Document Type: Article

References (26)

1. Heldmann F, Dybowski F, Saracbasi-Zender E, et al. Update on biologic therapy in the management of axial spondyloarthritis. Curr Rheumatol Rep 2010 Oct; 12 (5); 325-31
2. Colbert RA. Early axial spondyloarthritis. Curr Opin Rheumatol 2010 Sep; 22 (5); 603-7
3. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook; a guide to assess spondyloarthritis. Ann Rheum Dis 2009 Jun; 68 Suppl. II; ii1-44
4. Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol 2012 May; 8 (5); 262-8
5. LaSalle SP, Deodhar AA. Appropriate management of axial spondyloarthritis. Curr Rheumatol Rep 2007 Oct; 9 (5); 375-82
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report for Humira (adalimumab); procedure no. EMEA H C 000481 II 0085. online. Available from URL; :http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Assessment-Report-Variation/human/000481/WC500131935.pdf. Accessed 2012 Nov 28.
7. Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009 Jan; 68 (1); 18-24
8. The National Ankylosing Spondylitis Society. The Bath indices; outcome measures for use with ankylosing spondylitis patients. online. Available from URL; :http://www.nass.co.uk/NASS/en/loose-leaf-pages/bath-indices/. Accessed 2012 Nov 28.
9. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003 Feb; 62 (2); 127-32
10. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984 Apr; 27 (4); 361-8
11. European Medicines Agency. Humira 40 amg solution for injection; summary of product characteristics. online. Available from URL; :http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000481/ WC500050870.pdf. Accessed 2012 Nov 28.
12. Abbott Laboratories. Humira (adalimumab); US prescribing information. online. Available from URL; :http://www.rxabbott.com/pdf/humira.pdf. Accessed 2012 Nov 28.
13. Simpson D, Scott LJ. Adalimumab; in psoriatic arthritis. Drugs 2006 Aug; 66 (11); 1487-96
14. Cvetkovic RS, Scott LJ. Adalimumab; a review of its use in adult patients with rheumatoid arthritis. BioDrugs 2006 Oct; 20 (5); 293-311
15. Croom KF, McCormack PL. Adalimumab; in plaque psoriasis. Am J Clin Dermatol 2009 Jan; 10 (1); 43-50
16. Plosker GL, Lyseng-Williamson KA. Adalimumab; in Crohn's disease. BioDrugs 2007 Apr; 21 (2); 125-32
17. Bang LM, Keating GM. Adalimumab; a review of its use in rheumatoid arthritis. BioDrugs 2004 Mar; 18 (2); 121-39
18. den Broeder AA, Joosten LA, Saxne T, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis; effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002 Apr; 61 (4); 311-8
19. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis; results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008 Jul; 58 (7); 1981-91
20. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis; results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. Epub 2012 Jul 7
21. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, et al. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010 Apr; 38 (2-3); 82-9
22. European Medicines Agency. Humira-H-C-481-II-26; EPAR-scientific discussion-variation. online. Available from URL; :http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Scientific-Discussion-Variation/human/000481/ WC500050874.pdf. Accessed 2012 Nov 28.
23. Maksymowych WP, Mease PJ, Rao S, et al. Effect of adalimumab on function, health-related quality of life, work productivity, and daily activities in patients with non-radiographic axial spondyloarthritis. abstract no. 1312. Arthritis Rheum 2011 Oct; 63 Suppl. 10; s513
24. Sieper J, van Der Heijde D, Dougados M, et al. Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis; week 68 results from ABILITY 1. abstract no. THU0275. Ann Rheum Dis 2012; 71 Suppl. 3; 248
25. Haibel H, Heldmann F, Rudwaleit M, et al. Long-term efficacy of adalimumab for patients with active, non-radiographic, axial spondyloarthritis who relapsed following adalimumab withdrawal. abstract no. OP0027. Ann Rheum Dis 2010 Jun; 69 Suppl. 3; 59
26. Abbott. Study of adalimumab in subjects with axial spondyloarthritis. ClinicalTrials.gov identifier NCT00939003. US National Institutes of Health, ClinicalTrials.gov. online. Available from URL; :http://clinicaltrials.gov. Accessed 2012 Nov 28.